Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice.

Ghoneim HE, McCullers JA.

J Infect Dis. 2014 May 1;209(9):1459-68. doi: 10.1093/infdis/jit653. Epub 2013 Nov 23.

PMID:
24273183
2.

Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.

Karlström A, Boyd KL, English BK, McCullers JA.

J Infect Dis. 2009 Feb 1;199(3):311-9. doi: 10.1086/596051.

3.

Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza.

Karlström A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA.

J Infect Dis. 2011 Nov;204(9):1358-66. doi: 10.1093/infdis/jir522. Epub 2011 Sep 7.

4.

Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses.

Damjanovic D, Lai R, Jeyanathan M, Hogaboam CM, Xing Z.

Am J Pathol. 2013 Sep;183(3):868-80. doi: 10.1016/j.ajpath.2013.05.016. Epub 2013 Jul 4.

PMID:
23831294
5.

Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.

McCullers JA.

J Infect Dis. 2004 Aug 1;190(3):519-26. Epub 2004 Jun 30.

PMID:
15243927
6.

Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.

Fukushi M, Yamashita M, Miyoshi-Akiyama T, Kubo S, Yamamoto K, Kudo K.

PLoS One. 2012;7(8):e42419. doi: 10.1371/journal.pone.0042419. Epub 2012 Aug 1.

7.

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

McCullers JA, Bartmess KC.

J Infect Dis. 2003 Mar 15;187(6):1000-9. Epub 2003 Mar 6.

PMID:
12660947
8.

Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia.

Boyd AR, Hinojosa CA, Rodriguez PJ, Orihuela CJ.

BMC Microbiol. 2012 May 15;12:73. doi: 10.1186/1471-2180-12-73.

9.

Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection.

Fukuda Y, Furuya Y, Nozaki Y, Takahata M, Nomura N, Mitsuyama J.

Diagn Microbiol Infect Dis. 2014 Feb;78(2):168-71. doi: 10.1016/j.diagmicrobio.2013.11.003. Epub 2013 Nov 14.

PMID:
24321356
10.

IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection.

van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der Poll T.

J Immunol. 2004 Jun 15;172(12):7603-9.

11.

CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection.

Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD.

J Immunol. 2011 Jan 1;186(1):508-15. doi: 10.4049/jimmunol.1001002. Epub 2010 Nov 22.

12.

Limited anti-inflammatory role for interleukin-1 receptor like 1 (ST2) in the host response to murine postinfluenza pneumococcal pneumonia.

Blok DC, van der Sluijs KF, Florquin S, de Boer OJ, van 't Veer C, de Vos AF, van der Poll T.

PLoS One. 2013;8(3):e58191. doi: 10.1371/journal.pone.0058191. Epub 2013 Mar 6.

13.

Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia.

Müller-Redetzky HC, Wienhold SM, Berg J, Hocke AC, Hippenstiel S, Hellwig K, Gutbier B, Opitz B, Neudecker J, Rückert J, Gruber AD, Kershaw O, Mayer K, Suttorp N, Witzenrath M.

J Antimicrob Chemother. 2015 Mar;70(3):830-40. doi: 10.1093/jac/dku446. Epub 2014 Nov 17.

PMID:
25406299
14.

Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.

Hayashi K, Kadowaki SE, Takei M, Fukuda H.

Antimicrob Agents Chemother. 2006 Feb;50(2):748-51.

15.

Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.

Choi S, Im W, Bartizal K.

Antimicrob Agents Chemother. 2012 Sep;56(9):4713-7. doi: 10.1128/AAC.00346-12. Epub 2012 Jun 19.

16.

Interleukin-35 is upregulated in response to influenza virus infection and secondary bacterial pneumonia.

Chen Y, Wang CJ, Lin SH, Zhang M, Li SY, Xu F.

Cytokine. 2016 May;81:23-7. doi: 10.1016/j.cyto.2016.01.016. Epub 2016 Feb 5.

PMID:
26844658
17.

Aerosolized clindamycin is superior to aerosolized dexamethasone or clindamycin-dexamethasone combination in the treatment of severe Porphyromonas gingivalis aspiration pneumonia in an experimental murine model.

Nemec A, Pavlica Z, Nemec-Svete A, Eržen D, Milutinović A, Petelin M.

Exp Lung Res. 2012 Feb;38(1):9-18. doi: 10.3109/01902148.2011.632063. Epub 2011 Dec 8.

PMID:
22149928
18.

Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.

Reppe K, Tschernig T, Lührmann A, van Laak V, Grote K, Zemlin MV, Gutbier B, Müller HC, Kursar M, Schütte H, Rosseau S, Pabst R, Suttorp N, Witzenrath M.

Am J Respir Cell Mol Biol. 2009 Apr;40(4):474-81. doi: 10.1165/rcmb.2008-0071OC. Epub 2008 Oct 17.

PMID:
18931326
19.

Increase of apoptosis in a murine model for severe pneumococcal pneumonia during influenza A virus infection.

Kosai K, Seki M, Tanaka A, Morinaga Y, Imamura Y, Izumikawa K, Kakeya H, Yamamoto Y, Yanagihara K, Tomono K, Kohno S.

Jpn J Infect Dis. 2011;64(6):451-7.

20.

Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia.

Rijneveld AW, Florquin S, Hartung T, Speelman P, van der Poll T.

J Infect Dis. 2003 Jul 15;188(2):282-5. Epub 2003 Jul 9.

PMID:
12854084

Supplemental Content

Support Center